The weekly litigation news digest is live. Subscribe now

IP Verse

Dosage Regimen For A S1P Receptor Agonist - EP3409274

The patent EP3409274 was granted to Novartis on Nov 20, 2019. The application was filed on Dec 21, 2009 under application number EP18179301A. The patent is currently recorded with a legal status of "Revoked".

EP3409274

NOVARTIS
Application Number
EP18179301A
Filing Date
Dec 21, 2009
Status
Revoked
Dec 6, 2024
Publication Date
Nov 20, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status
HAMM & WITTKOPPAug 18, 2020-WITHDRAWN
VON SEEBACHAug 18, 2020HAMM & WITTKOPPWITHDRAWN

Patent Citations (6) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP0627406
DESCRIPTIONWO0218395
DESCRIPTIONWO03097028
SEARCHWO2006058316
SEARCHWO2009115954
SEARCHWO2010072703

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents